medmix wins 2024 BIG Innovation Award

medmix' MIXPAC greenLine 400 mL 1:1 two-component cartridge, launched in May 2023, has been selected as a winner in the construction category at the 2024 BIG Innovation Awards presented by the Business Intelligence Group (BIG). The cartridge set is an innovative product made from up to 100% post-consumer recycled (PCR) plastics, significantly reducing its CO2 footprint by up to 38% without compromising quality.

Designed for seamless integration into existing dispensers compatible with MIXPAC 400mL 1:1 cartridges, medmix’ novel solution offers a reduced carbon footprint and supports the circular economy without requiring any process changes. This sustainable innovation aims to bridge the gap between environmental responsibility and industrial efficiency while maintaining the same high-performance standards as the conventional MIXPAC cartridges.

medmix is set to participate in the upcoming World of Concrete event in Las Vegas, January 23-25. This key industry event offers an exceptional platform to highlight the distinct features and benefits of medmix’ newest development, reflecting the company’s focus on innovation and sustainability. In addition to the MIXPAC greenLine systems, medmix will be showcasing MIXPAC ecopaCC™, a CO2-reducing two-component system as well as the new rackless cordless dispenser COXTM speedfleX™ marking its first-time presentation.

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’600 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

Inquiries:

Media Relations: Roland Loacker, medmix communications@medmix.com

Investor Relations: James Amoroso, medmix investorrelations@medmix.com

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.